One or two doses of psilocybin eased depression for months in a review of eight studies

Depression affects 280 million people worldwide, carries a high mortality rate and is a leading cause of disability. For a meaningful share of those people, standard approaches fall short: some live with treatment-resistant depression, and others face depression arising from a life-threatening illness such as cancer. Psychedelic compounds, psilocybin chief among them, have attracted growing scientific attention as a different route into treating mood disorders. The question this review set out to answer is what the experimental evidence actually says about combining psilocybin with psychotherapy for major depressive disorder.

Researchers in the health psychology department at Miguel Hernández University in Spain systematically reviewed the published literature on therapeutic procedures using psilocybin for major depressive disorder. They identified eight studies examining the condition. Some of those studies involved people with treatment-resistant depression, whose symptoms had not responded to conventional care, while others involved depression linked to a life-threatening disease such as cancer. In each case, psilocybin was delivered in one or two doses, in conjunction with psychological support throughout the process.

The publications reviewed affirm the efficiency of psilocybin therapy for depression when delivered with only one or two doses alongside psychological support. Reported benefits include a rapid improvement in depressive symptoms and an increased sense of well-being that can last for months after the treatment. The review also notes a greater development of introspective capacity among those treated. What the review cannot supply is a precise pooled size for these effects, since it summarises eight separate publications rather than combining their numbers statistically.

This review lands in the middle of a broader revival of psychedelic research, and it supports the pattern seen in earlier reports: psilocybin appears to act quickly, and its benefits appear to outlast the dose by months. Eight studies remains a thin evidence base for any treatment, and the populations covered range from treatment-resistant depression to depression linked to cancer, which are quite different clinical situations. Open questions include how psilocybin compares with standard antidepressants over the long term, how much of the benefit depends on the accompanying psychological support, and whether the results hold at larger scale.

The honest reading is that psilocybin therapy for depression is promising and still young. Every study in this review paired the drug with structured psychological support, so the evidence describes a supervised therapeutic procedure, not a substance taken alone. For a reader following the psychedelics story, this is a reason to take the depression findings seriously while remembering how few studies exist. It is not a treatment most people can currently access, and nothing here speaks to unsupervised use.